MedTrace Logo

Neurotransmitter Levels in Children With Specific Learning Disorder

NCT07240142 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-11-20

No results posted yet for this study

Summary

The aim of this clinical trial was to measure how specific neurotransmitter levels in children with Specific Learning Disorder (SLD) change compared to controls. The relationship between these markers and the measured markers will be determined both theoretically and experimentally using various neuropsychological tests. The fundamental questions it aims to answer are

Did neurotransmitter levels increase or decrease in the patient group? Are the neurotransmitter levels measured in the neuropsychological tests related? Can the measured neurotransmitters be used to predict the disease?

Participants:

A single visit to the clinic, a blood sample, and neuropsychological tests will be administered on the same day.

Conditions

  • Specific Learning Disability
  • Healthy (Controls)

Interventions

PROCEDURE

Blood Product

Collecting 5 ml blood samples from the left atrial vein, after that obtaining serum from it.

OTHER

Elisa test

Measurement of glutamate, nitric oxide, and L-arginine concentrations in the blood samples obtained using an ELISA test kit.

Sponsors & Collaborators

  • Dilara Ulger Ozbek

    lead OTHER

Principal Investigators

  • Dilara ULGER OZBEK, Dr. · Cumhuriyet University

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
7 Years
Max Age
14 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-10-22
Primary Completion
2020-10-21
Completion
2021-04-16

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07240142 on ClinicalTrials.gov